CCR8 and neoplasm: Taken together, these observations of expansion of several immune cells in TME post 225Ac-anti-CCR8 RIT align with the decreased tumor growth observed after 225Ac-anti-CCR8 and CTLA-4 immunotherapy combination treatment.